Pacific Biosciences of California, Inc. (PACB)

1,6000 +0,1300 (+8,84 %) À la clôture : 04:00PM EDT

Pacific Biosciences of California, Inc.

1305 O’Brien Drive
Menlo Park, CA 94025
United States
650 521 8000
https://www.pacb.com

Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 796

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Christian O. Henry M.B.A.	President, CEO & Director	1,1M	S.O.	1968
Ms. Susan G. Kim	Chief Financial Officer	564,87k	S.O.	1976
Mr. Mark Van Oene	Chief Operating Officer	772,11k	S.O.	1973
Mr. Jeff Eidel	Chief Commercial Officer	435,62k	S.O.	1977
Dr. Stephen Turner Ph.D.	Co-Founder	341,25k	S.O.	1968
Trevin Rard	Head of Investor Relations	S.O.	S.O.	S.O.
Dr. Brett Atkins J.D., Ph.D.	General Counsel & Corporate Secretary	S.O.	S.O.	S.O.
Ms. Natalie Welch	Chief People Officer	S.O.	S.O.	S.O.
Dr. Denis Zaccarin Ph.D.	Senior Vice President of Research & Development	510,77k	4,34M	1966
Mr. Mike Goloubef	Senior Vice President of Manufacturing & Quality	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Pacific Biosciences of California, Inc. en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 6; Société : 3; Droits des actionnaires : 4; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.